Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

467
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
467
Seizures: Classification01:13

Seizures: Classification

629
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
629
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

298
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
298
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

210
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
210
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

294
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
294
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

531
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
531

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Vagus Nerve Stimulation on Suicidal Ideation in Markedly Treatment-Resistant Major Depression: A RECOVER Study Report.

The Journal of clinical psychiatry·2026
Same author

Vagus Nerve Stimulation differentially modulates P3b in responders and non-responders: toward a biomarker of therapeutic efficacy.

Frontiers in neuroscience·2026
Same author

Expanding the phenotypic spectrum of FGF12-epilepsy-does prompt precision therapy affect outcomes?

NPJ genomic medicine·2026
Same author

Effectiveness and safety of implantable vagus nerve stimulation in people with primary generalized tonic-clonic seizures.

Epilepsia open·2026
Same author

Adjunctive cenobamate in children and adolescents - real-world data from a retrospective multicenter study.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026
Same author

Effect of epileptogenesis on hypercapnic cardioventilatory response in kainic acid rats.

Epilepsia·2026

Related Experiment Video

Updated: Sep 21, 2025

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.6K

VNS parameters for clinical response in Epilepsy.

Firas Fahoum1, Massimiliano Boffini2, Lennart Kann2

  • 1EEG and Epilepsy Unit, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Brain Stimulation
|June 1, 2022
PubMed
Summary

This study identified optimal dosing for vagus nerve stimulation (VNS) therapy in epilepsy, finding a target output current of 1.61 mA and 17.1% duty cycle. Achieving this dose may improve seizure reduction, even for long-term patients.

Keywords:
Drug resistant epilepsyTitrationVagus nerve stimulation

More Related Videos

Transauricular Vagus Nerve Stimulation and Electroencephalographic Assessment in Disorders of Consciousness
04:04

Transauricular Vagus Nerve Stimulation and Electroencephalographic Assessment in Disorders of Consciousness

Published on: July 11, 2025

365
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.9K

Related Experiment Videos

Last Updated: Sep 21, 2025

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.6K
Transauricular Vagus Nerve Stimulation and Electroencephalographic Assessment in Disorders of Consciousness
04:04

Transauricular Vagus Nerve Stimulation and Electroencephalographic Assessment in Disorders of Consciousness

Published on: July 11, 2025

365
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.9K

Area of Science:

  • Neurology
  • Biomedical Engineering
  • Clinical Therapeutics

Background:

  • Vagus nerve stimulation (VNS) therapy has been used for over 20 years for epilepsy treatment.
  • Limited pre-market evidence has resulted in a lack of professional guidance on VNS dosing and titration.
  • Post-market surveillance shows significant deviations from recommended VNS dosing protocols.

Purpose of the Study:

  • To identify a target dose for VNS therapy specifically for epilepsy management.
  • To establish evidence-based parameters for optimizing VNS treatment outcomes in epilepsy patients.

Main Methods:

  • A generalized linear mixed model analyzed data from 1178 epilepsy patients undergoing VNS therapy.
  • Key stimulation parameters (output current, pulse width, frequency, duty cycle) were correlated with clinical response (≥50% seizure frequency reduction).
  • Demographic factors like epilepsy duration and age at implant were also explored.

Main Results:

  • A population-level target dose for VNS in epilepsy was determined: 1.61 mA output current and 17.1% duty cycle.
  • Shorter epilepsy duration was associated with a higher likelihood of positive VNS response (p < 0.001).
  • Longer-term VNS therapy correlated with better response, indicating potential benefits for underdosed patients upon dose adjustment.

Conclusions:

  • Aligning clinical practice with the identified evidence-based target dose can enhance VNS therapy outcomes for epilepsy.
  • This study provides crucial data to refine VNS dosing strategies for improved seizure control.
  • Further research into personalized VNS titration based on patient-specific factors is warranted.